drug discovery

Three tech-driven companies—Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics—are positioned to reshape healthcare through AI, precision medicine, and faster drug discovery by 2030.

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.

AbbVie and adMare BioInnovations award RIME Therapeutics the AbbVie Biotech Innovators Prize, providing lab space, equipment, and executive mentorship.

AbbVie awards RIME Therapeutics incubation support at Montreal's adMare Centre, providing laboratory space, equipment access, and mentorship for its inflammation-focused peptide platform.

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

Novo Nordisk partners with OpenAI to deploy AI across drug discovery, clinical trials, manufacturing, and supply chain operations, targeting pilot programs by end of 2026.

Neurocrine Biosciences doses first patient in Phase 2 trial of NBI-1117570 for schizophrenia, triggering $22.5M milestone payment to partner Nxera Pharma.

Nxera Pharma achieves second milestone with Eli Lilly validating its GPCR-targeting platform. Deal includes $694M in potential payments plus royalties.

Eli Lilly commits $10B to AI drug discovery partnership and sleep disorders acquisition, diversifying beyond its GLP-1 franchise.

Eli Lilly bets on AI-driven drug discovery alongside its $11B weight loss drug franchise, partnering with Nvidia and Insilico Medicine to build next-generation blockbusters.

Merck partners with Infinimmune for next-gen antibody drugs, gaining exclusive rights to candidates from AI-powered platform with up to $838M in potential milestone payments.

Eli Lilly acquires Centessa Pharmaceuticals, which developed sleep-disorder treatments with Nxera Pharma. Nxera retains royalties, milestones, and equity stake.

Eli Lilly acquires Centessa Pharmaceuticals, developer of OX2R agonists for sleep disorders co-created with Nxera Pharma, which retains milestone payments and royalties.

Recursion expands Citeline partnership to integrate real-world data into its AI drug discovery platform, achieving 30-60% trial enrollment improvements.

BullFrog AI ($BFRG) launches bfARENAS, a scenario-based decision engine designed to optimize drug portfolio strategy and clinical trial design for biotech firms.

Zealand Pharma opens Cambridge research hub in September 2026 to expand AI-driven drug discovery and develop next-generation hybrid molecule therapeutics.

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.

Roche and NVIDIA expand AI infrastructure with 2,176 on-premises GPUs across U.S. and Europe, totaling 3,500 Blackwell units to accelerate drug discovery and diagnostics.

Tecan and NVIDIA collaborate to develop AI-enabled laboratory platforms, integrating GPU-accelerated models to accelerate drug discovery and lab productivity.